Exploring the role of individual PI3K isoforms in different cells of the tumor microenvironment may contribute to the design of more effective combination therapies, because these inhibitors can be tolerated at doses leading to greater effective inhibition of their targets. This evidence concerns the gene PIK3CB and neoplasm.